Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
AstraZeneca
Mallinckrodt
Express Scripts
Moodys

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Dacetuzumab

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Dacetuzumab?

Dacetuzumab is an investigational drug.

There have been 7 clinical trials for Dacetuzumab. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2006.

The most common disease conditions in clinical trials are Lymphoma, Non-Hodgkin, Lymphoma, and Lymphoma, Large B-Cell, Diffuse. The leading clinical trial sponsors are Seattle Genetics, Inc., Genentech, Inc., and [disabled in preview].

Recent Clinical Trials for Dacetuzumab
TitleSponsorPhase
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCLGenentech, Inc.Phase 1
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCLSeattle Genetics, Inc.Phase 1
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCLGenentech, Inc.Phase 2

See all Dacetuzumab clinical trials

Clinical Trial Summary for Dacetuzumab

Top disease conditions for Dacetuzumab
Top clinical trial sponsors for Dacetuzumab

See all Dacetuzumab clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Colorcon
Harvard Business School
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.